| References | Case-control studies | Salivary TAC percentage () | Urinary TAC percentage () | Treatment effect percentage () |
| [19, 37, 46, 50, 55, 56, 91, 100, 101, 107, 119, 129, 144] | Metabolic syndrome symptoms | 41.7% (5/12) 33.3% (4/12) 25% (3/12) | | Salivary TAC 100% (1/1) enalapril 100% (1/1) metoprolol 100% (1/1) rasburicase Urinary TAC 100% (1/1) PCI 100% (1/1) NAC before and after PCI |
| [59, 74, 118, 152, 165] | Cancer | 66.7% (2/3) 33.3% (1/3) | 66.7% (2/3) 33.3% (1/3) | Salivary TAC chemotherapy |
| [42, 105, 111, 117, 150, 167] | Neuropsychiatric disorders | 75% (3/4) 25% (1/4) | ↓ 100% (2/2) | |
| [43, 82, 116, 146, 151, 156, 163, 169] | Congenital and genetic diseases | 33.3% (1/3) 33.3% (1/3) 33.3% (1/3) | ↓ 83.3% (5/6) ↑ 16.7% (1/6) | Urinary TAC: 100% (3/3) low-protein diet + L-carnitine in IEM patients |
| [33, 38, 48, 58, 65, 106, 108, 109, 123, 126, 132, 135] | Immune mediated and inflammatory diseases | ↓ 60% (6/10) ↑ 40% (4/10) | | Salivary TAC 100% (1/1) corticosteroid 100% (2/2) CPAP in OSAS 100% (1/1) anti-TNF therapy |
|
|